{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:33:42Z","timestamp":1790872422987,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.ijantimicag.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T10:25:22Z","timestamp":1304936722000},"page":"192-196","source":"Crossref","is-referenced-by-count":53,"title":["Daptomycin: evaluation of a high-dose treatment strategy"],"prefix":"10.1016","volume":"38","author":[{"given":"Gary","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teena","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Rapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Vastey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Balmir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1592\/phco.2005.25.7.1001","article-title":"Gram-positive resistance: pathogens, implications, and treatment options: insights from the Society of Infectious Diseases Pharmacists","volume":"25","author":"Akins","year":"2005","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.diagmicrobio.2009.10.011","article-title":"Linezolid surveillance program results for 2008 (LEADER Program for 2008)","volume":"65","author":"Farrell","year":"2009","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0015","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0020","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","article-title":"Safety and clinical outcomes when utilizing high-dose (\u22658mg\/kg) daptomycin therapy","volume":"43","author":"Moise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1592\/phco.24.1.41.34802","article-title":"Daptomycin","volume":"24","author":"Tedesco","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0035","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0040","series-title":"Cubicin (daptomycin) package insert","author":"Cubist Pharmaceuticals","year":"2010"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0045","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1128\/AAC.00559-07","article-title":"Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis","volume":"51","author":"Julian","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0050","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/jac\/dkn105","article-title":"Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis","volume":"61","author":"Hidron","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0055","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.49.4.1664-1665.2005","article-title":"Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy","volume":"49","author":"Lewis","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0060","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0065","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1742-1241.2008.01854.x","article-title":"A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by Gram-positive bacteria","volume":"62","author":"Katz","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/600039","article-title":"Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program","volume":"49","author":"Figueroa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","article-title":"High-dose daptomycin in documented Staphylococcus aureus infections","volume":"36","author":"Bassetti","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.hrtlng.2007.04.003","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin","volume":"37","author":"Cunha","year":"2008","journal-title":"Heart Lung"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0085","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1345\/aph.1M324","article-title":"Multidrug-resistant Enterococcus faecium endocarditis treated with combination tigecycline and high-dose daptomycin","volume":"43","author":"Schutt","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hrtlng.2005.09.010","article-title":"Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: cure with prolonged\/high-dose daptomycin without toxicity","volume":"35","author":"Cunha","year":"2006","journal-title":"Heart Lung"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0095","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1086\/648115","article-title":"Early experience with high dosage daptomycin for prosthetic infections","volume":"49","author":"De Rosa","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijantimicag.2009.08.019","article-title":"High-dose daptomycin for the treatment of endocarditis caused by Staphylococcus aureus with intermediate susceptibility to glycopeptides","volume":"35","author":"Lichterfeld","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/jac\/46.4.523","article-title":"Development of daptomycin for Gram-positive infections","volume":"46","author":"Tally","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0110","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/383472","article-title":"Daptomycin: another novel agent for treating infections due to drug-resistant Gram-positive pathogens","volume":"38","author":"Carpenter","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2011.03.006_bib0115","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1086\/647938","article-title":"Daptomycin: from the mountain to the clinic with essential help from Francis Tally, MD","volume":"50","author":"Eisenstein","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0120","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.47.5.1598-1603.2003","article-title":"Daptomycin dose\u2013effect relationship against resistant Gram-positive organisms","volume":"47","author":"Cha","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0125","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1086\/520655","article-title":"Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus","volume":"45","author":"Boucher","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000109868","article-title":"Daptomycin: a review 4 years after first approval","volume":"81","author":"Sauermann","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0135","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0140","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1128\/AAC.00102-08","article-title":"Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"52","author":"Rose","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2011.03.006_bib0145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jac\/dkm170","article-title":"Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies","volume":"60","author":"Rose","year":"2007","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791100149X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485791100149X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T22:53:46Z","timestamp":1543791226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485791100149X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S092485791100149X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2011.03.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}